Crinetics Pharmaceuticals Inc
CRNXHealthcare|Biotechnology|USA
$83.58
-0.04 (-0.05%)
Tangible Book
$12.16
About
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Stock Price
+161.3%(1Y)
Pipeline Summary
19 total trials8
Phase 1
9
Phase 2
5
Phase 3
0
Phase 4
Recruiting: 6Active: 4Completed: 9
Active Trials (10)
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia
Phase 2Recruiting
Enrollment: 200 participants
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
NCT05804669Cushing Syndrome
Phase 1Phase 2Recruiting
Enrollment: 18 participants
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
NCT05192382Acromegaly
Phase 3Active
Enrollment: 111 participants
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome
Phase 3Recruiting
Enrollment: 141 participants
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms
Phase 1Phase 2Recruiting
Enrollment: 150 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
Vivaldi Coelho RogerioSELL
2026-07-023,000 shares @ $40
Okey StephanieSELL
2026-06-176,900 shares @ $35.67
Knight Jeff E.SELL
2026-04-0885,163 shares @ $40.1
Betz Stephen F.SELL
2026-03-1610,612 shares @ $37.37
Knight Jeff E.SELL
2026-03-169,911 shares @ $37.37
Recent News
2026-07-10 00:00:03
2026-07-09 19:53:16
2026-07-09 18:00:04
2026-07-08 17:00:05
2026-07-08 16:34:25
Data last updated: Jul 12, 2026, 07:38 PM